Kempner Capital Management Inc. Sells 27,095 Shares of Zimmer Biomet Holdings, Inc. $ZBH

Kempner Capital Management Inc. lowered its holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 46.3% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 31,401 shares of the medical equipment provider’s stock after selling 27,095 shares during the quarter. Zimmer Biomet makes up 2.6% of Kempner Capital Management Inc.’s portfolio, making the stock its 15th biggest position. Kempner Capital Management Inc.’s holdings in Zimmer Biomet were worth $3,093,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. Resona Asset Management Co. Ltd. boosted its position in Zimmer Biomet by 5.7% during the second quarter. Resona Asset Management Co. Ltd. now owns 67,915 shares of the medical equipment provider’s stock valued at $6,197,000 after purchasing an additional 3,634 shares in the last quarter. QSM Asset Management Ltd lifted its position in shares of Zimmer Biomet by 36.1% during the second quarter. QSM Asset Management Ltd now owns 111,500 shares of the medical equipment provider’s stock valued at $10,174,000 after buying an additional 29,600 shares during the last quarter. Truist Financial Corp boosted its holdings in shares of Zimmer Biomet by 34.4% in the 2nd quarter. Truist Financial Corp now owns 26,819 shares of the medical equipment provider’s stock valued at $2,446,000 after buying an additional 6,867 shares in the last quarter. Magellan Asset Management Ltd grew its position in shares of Zimmer Biomet by 16.8% in the 2nd quarter. Magellan Asset Management Ltd now owns 505,901 shares of the medical equipment provider’s stock worth $46,143,000 after buying an additional 72,613 shares during the last quarter. Finally, State of Alaska Department of Revenue raised its stake in shares of Zimmer Biomet by 89.8% during the 2nd quarter. State of Alaska Department of Revenue now owns 44,261 shares of the medical equipment provider’s stock worth $4,036,000 after acquiring an additional 20,945 shares in the last quarter. 88.89% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on the stock. Weiss Ratings restated a “hold (c-)” rating on shares of Zimmer Biomet in a research note on Wednesday, October 8th. Stifel Nicolaus set a $110.00 price objective on Zimmer Biomet in a research report on Wednesday, November 5th. Johnson Rice set a $112.00 target price on Zimmer Biomet in a research report on Wednesday, November 5th. Royal Bank Of Canada decreased their price target on Zimmer Biomet from $111.00 to $101.00 and set an “outperform” rating for the company in a research note on Thursday, November 6th. Finally, Wall Street Zen lowered Zimmer Biomet from a “buy” rating to a “hold” rating in a research note on Sunday, November 16th. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, twelve have issued a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $107.50.

Zimmer Biomet Stock Performance

Shares of ZBH opened at $90.78 on Friday. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.39 and a current ratio of 2.43. The stock has a 50-day moving average of $94.07 and a two-hundred day moving average of $96.57. The stock has a market cap of $17.99 billion, a P/E ratio of 22.47, a P/E/G ratio of 2.37 and a beta of 0.61. Zimmer Biomet Holdings, Inc. has a one year low of $85.33 and a one year high of $114.44.

Zimmer Biomet (NYSE:ZBH) last announced its quarterly earnings data on Wednesday, November 5th. The medical equipment provider reported $1.90 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.88 by $0.02. The firm had revenue of $2 billion during the quarter, compared to analysts’ expectations of $2.01 billion. Zimmer Biomet had a return on equity of 12.85% and a net margin of 10.05%.The company’s revenue for the quarter was up 9.6% compared to the same quarter last year. During the same period last year, the business posted $1.74 earnings per share. Zimmer Biomet has set its FY 2025 guidance at 8.100-8.300 EPS. As a group, research analysts predict that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current year.

Zimmer Biomet Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, January 30th. Shareholders of record on Tuesday, December 30th will be paid a dividend of $0.24 per share. This represents a $0.96 annualized dividend and a yield of 1.1%. The ex-dividend date is Tuesday, December 30th. Zimmer Biomet’s payout ratio is presently 23.76%.

About Zimmer Biomet

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.